Dendreon

Visit our Filed page for categories. To browse by specific topic, see our Inside page. For a list of companies covered on this site, visit our Companies page.

 

FDA orders halt to some Provenge marketing

The Food and Drug Administration has asked Dendreon Corp.  to stop using some promotional materials for Provenge, saying they are “false or misleading” because they omit or minimize the prostate-cancer drug’s risks and overstate its effectiveness.

Provenge, which was approved by the agency in late April, is seen as the first in a new class of cancer-fighting drugs that use a patient’s cells to stimulate the body’s immune system to fight cancer. Get the full story »